PCI Biotech Holding ASA (PCIB) — Working Capital to Net Assets Ratio
PCI Biotech Holding ASA (PCIB) has a Working Capital to Net Assets ratio of 93.2% as of June 2025. Working capital of Nkr11.66 Million (current assets of Nkr17.67 Million minus current liabilities of Nkr6.01 Million) is measured against net assets of Nkr12.52 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See PCIB financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
PCI Biotech Holding ASA Working Capital to Net Assets (2008–2024)
This chart shows how PCI Biotech Holding ASA's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2008 to 2024. As of June 2025, the ratio stands at 93.2%, reflecting working capital of Nkr11.66 Million against net assets of Nkr12.52 Million NOK. See PCI Biotech Holding ASA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for PCI Biotech Holding ASA (2008–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for PCI Biotech Holding ASA from 2008 to 2024, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see PCI Biotech Holding ASA market cap and net worth.
| Year | WC/NA Ratio | Working Capital (NOK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 98.7% | Nkr23.14 Million | Nkr23.45 Million | Nkr30.91 Million | Nkr7.76 Million | ▼ -0.6 pp |
| 2023 | 99.3% | Nkr38.78 Million | Nkr39.04 Million | Nkr43.75 Million | Nkr4.97 Million | ▲ +0.0 pp |
| 2022 | 99.3% | Nkr57.01 Million | Nkr57.40 Million | Nkr62.76 Million | Nkr5.75 Million | ▲ +4.9 pp |
| 2021 | 94.4% | Nkr107.41 Million | Nkr113.79 Million | Nkr128.32 Million | Nkr20.91 Million | ▼ -1.4 pp |
| 2020 | 95.8% | Nkr181.28 Million | Nkr189.24 Million | Nkr201.13 Million | Nkr19.85 Million | ▼ -2.8 pp |
| 2019 | 98.5% | Nkr251.12 Million | Nkr254.83 Million | Nkr275.75 Million | Nkr24.63 Million | ▼ -1.5 pp |
| 2018 | 100.0% | Nkr340.04 Million | Nkr339.95 Million | Nkr357.04 Million | Nkr17.00 Million | ▼ -4.7 pp |
| 2017 | 104.7% | Nkr43.83 Million | Nkr41.84 Million | Nkr58.41 Million | Nkr14.59 Million | ▲ +4.8 pp |
| 2016 | 100.0% | Nkr13.08 Million | Nkr13.09 Million | Nkr22.39 Million | Nkr9.31 Million | ▼ 0.0 pp |
| 2015 | 100.0% | Nkr44.27 Million | Nkr44.28 Million | Nkr56.39 Million | Nkr12.12 Million | ▲ +0.1 pp |
| 2014 | 99.8% | Nkr9.10 Million | Nkr9.11 Million | Nkr20.37 Million | Nkr11.27 Million | ▼ -0.4 pp |
| 2013 | 100.2% | Nkr43.50 Million | Nkr43.40 Million | Nkr52.72 Million | Nkr9.22 Million | ▼ -1.0 pp |
| 2012 | 101.2% | Nkr70.53 Million | Nkr69.71 Million | Nkr78.20 Million | Nkr7.67 Million | ▼ -0.7 pp |
| 2011 | 101.9% | Nkr94.32 Million | Nkr92.53 Million | Nkr100.15 Million | Nkr5.83 Million | ▼ -0.4 pp |
| 2010 | 102.3% | Nkr107.86 Million | Nkr105.42 Million | Nkr114.46 Million | Nkr6.61 Million | ▲ +2.8 pp |
| 2009 | 99.5% | Nkr34.90 Million | Nkr35.08 Million | Nkr41.35 Million | Nkr6.45 Million | ▼ -0.1 pp |
| 2008 | 99.6% | Nkr49.10 Million | Nkr49.30 Million | Nkr54.38 Million | Nkr5.28 Million | — |